Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression We report results from a multicenter, placebo-controlled, randomized, double-blind comparison of the efficacy and tolerability of paroxetine and fluoxetine in outpatients with major depression. Across five U.S. sites, 128 outpatients (mean age: 41.3 ± 12.6; 63 men and 65 women) with moderate to moderately severe major depression without a history of mania or hypomania were recruited between 1993 and 1994. All 128 patients completed a 1-week placebo washout period, and were then randomized to 12 weeks of double-blind treatment with paroxetine up to 50 mg/day (n = 55), fluoxetine up to 80 mg/day (n = 54), or placebo (n = 19). Subjects were evaluated weekly for the first 4 weeks, then at weeks 6, 9, and 12 with the 21-item HAMD and the Covi Anxiety Scale. There were no significant differences among the three treatment groups in baseline and endpoint depression and anxiety severity, as well as in the degree of depression and anxiety improvement. There were no statistically significant differences in rates or mean numbers of adverse events between paroxetine-treated patients and fluoxetine-treated patients. In summary, our results, although limited by the lack of a significant difference from placebo in treatment outcome, suggest that the SSRIs paroxetine and fluoxetine have comparable antidepressant and antianxiety efficacies among depressed outpatients, as well as similar safety and tolerability profiles. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/a-double-blind-study-of-paroxetine-fluoxetine-and-placebo-an-dZtX8zgR46
Publisher
Springer Journals
Copyright
Copyright © 1998 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022337927842
Publisher site
See Article on Publisher Site

Abstract

We report results from a multicenter, placebo-controlled, randomized, double-blind comparison of the efficacy and tolerability of paroxetine and fluoxetine in outpatients with major depression. Across five U.S. sites, 128 outpatients (mean age: 41.3 ± 12.6; 63 men and 65 women) with moderate to moderately severe major depression without a history of mania or hypomania were recruited between 1993 and 1994. All 128 patients completed a 1-week placebo washout period, and were then randomized to 12 weeks of double-blind treatment with paroxetine up to 50 mg/day (n = 55), fluoxetine up to 80 mg/day (n = 54), or placebo (n = 19). Subjects were evaluated weekly for the first 4 weeks, then at weeks 6, 9, and 12 with the 21-item HAMD and the Covi Anxiety Scale. There were no significant differences among the three treatment groups in baseline and endpoint depression and anxiety severity, as well as in the degree of depression and anxiety improvement. There were no statistically significant differences in rates or mean numbers of adverse events between paroxetine-treated patients and fluoxetine-treated patients. In summary, our results, although limited by the lack of a significant difference from placebo in treatment outcome, suggest that the SSRIs paroxetine and fluoxetine have comparable antidepressant and antianxiety efficacies among depressed outpatients, as well as similar safety and tolerability profiles.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 13, 2004

References

  • Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions
    Finley, PR
  • A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression
    Schone, W; Ludwig, M
  • A rating scale for depression
    Hamilton, M
  • A new depression scale designed to be sensitive to change
    Montgomery, SA; Asberg, M
  • A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression
    Tignol, J
  • A double-blind, comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients
    De Wilde, J; Spiers, R; Mertens, C; Bartholome, F; Schotte, G; Leyman, S
  • Factors of psychopathology in interview, word behavior, and self-report ratings of hospitalized depressions
    Raskin, A; Schulterbrandt, J; Reatig, N; Rice, CE
  • Symptomatic volunteers in multicenter drug trials
    Covi, L; Lipman, R; McNair, DM; Czerlinsky, T
  • National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments
    Elkin, I; Shea, MT; Watkins, JT; Imber, SD; Sotsky, SM; Collins, JF; Glass, DR; Pilkonis, PA; Leber, WR; Docherty, JP; Fiester, SJ; Parloff, MB
  • SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective-multicenter, and descriptive clinical study of 344 patients
    Montejo-Gonzalez, AL; Llorca, G; Izquierdo, JA; Ledesma, A; Bousono, M; Calcedo, A; Carrasco, JL; Ciudad, J; Daniel, E; De La Gandara, J; Derecho, J; Franco, M; Gomez, MJ; Macias, JA; Martin, T; Perez, V; Sanchez, JM; Sanchez, S; Vicens, E